ClinicalTrials.gg
CompletedNCT04137380Updated Jan 26, 2024Results posted

A Study of Mirikizumab in Healthy Chinese Participants

A Phase 1 interventional study of Mirikizumab - IV and Mirikizumab - SC in Healthy, sponsored by Eli Lilly and Company. Completed at 2 sites in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-26.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The main purpose of this study is to evaluate the safety of the study drug known as mirikizumab. The study will investigate how the body processes the study drug. It will last up to about 4 months for each participant.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Native Chinese (all 4 biological grandparents and both biological parents to be Chinese origin)
  • Have a (BMI) of 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive, at time of screening
  • Have clinical laboratory test results within normal reference range for the investigative site or results with acceptable deviations that are judged to be not by the investigator
  • Have venous access sufficient to allow for blood sampling and administration of product (IP) or placebo
  • Are reliable and willing to be available for the duration of the study and are willing to follow study procedures
  • Are able and willing to give signed

Exclusion criteria

Exclusion Criteria:

  • Are currently enrolled in a clinical study involving an IP or any other type of medical research judged not to be scientifically or medically compatible with this study
  • Have participated in a clinical trial involving an IP within 30 days or 5 half-lives (whichever is longer) prior to screening. If the clinical trial involved treatment with biologic agents (such as monoclonal antibodies, including marketed drugs), at least 3 months or 5 half-lives (whichever is longer) should have elapsed prior to Day 1
  • Have known allergies to LY3074828, humanized monoclonal antibodies, related compounds or any components of the formulation, or history of significant atopy
  • Show evidence of (HIV) infection and/or positive human HIV antibodies
  • Show evidence of and/or positive hepatitis C antibody
  • Show evidence of and/or positive hepatitis B surface antigen or positive hepatitis B core antibody
  • Have had symptomatic herpes zoster within 3 months of screening
  • Show evidence of active or latent tuberculosis (TB), as documented by medical history, examination, chest X-rays (posterior/anterior and lateral), and TB testing (positive or indeterminate for QuantiFERON® -TB Gold test or T-Spot. 1 retest permitted following indeterminate result); or have had household contact with a person with active TB, unless appropriate and documented prophylaxis treatment has been given. Participants with any history of active TB are excluded from the study, regardless of previous or current TB treatments.
  • Have received (s), including attenuated live vaccines and those administered intranasally, within 8 weeks of screening, or intend to during the study
  • Are
  • Have multiple or severe drug allergies, or intolerance to topical , or severe post treatment reactions (including, but not limited to, erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, or exfoliative dermatitis)
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Mirikizumab - Intravenous (IV)

    Participants received a single dose of 300 milligram (mg), 600 mg and 1200 mg mirikizumab administered IV using a forearm vein infused over at least 30 minutes, 60 minutes and 2 hours.

    Drug: Mirikizumab - IV

  • Placebo comparator
    Placebo - IV

    Participants received a single dose of placebo administered IV using a forearm vein.

    Drug: Placebo - IV

  • Experimental
    Mirikizumab - Subcutaneous (SC)

    Participants received a single dose of 200 mg, 400 mg mirikizumab administered SC as 2 injections, 1 into the skinfold of each lower abdominal wall quadrant (left and right).

    Drug: Mirikizumab - SC

  • Placebo comparator
    Placebo - SC

    Participants received a single dose of placebo administered SC as 2 injections, 1 into the skinfold of each lower abdominal wall quadrant (left and right).

    Drug: Placebo - SC

Interventions

  • Administered IV

    Also known as: LY3074828

  • Administered SC

    Also known as: LY3074828

  • DrugPlacebo - IV

    Administered IV

  • DrugPlacebo - SC

    Administered SC

06

What researchers measure

Primary outcomes

  1. Number of Participants With One or More Drug-Related Treatment-Emergent Adverse Events (TEAEs)

    Drug-related TEAEs are any untoward medical occurrence that either occurs or worsens at any time after treatment baseline, and in the opinion of the investigators is possibly related to study drug. A summary of serious adverse events (SAEs) and other non-serious adverse events (NSAEs), regardless of whether or not they were possibly related to study drug, is located in the Reported Adverse Event section.

    Time frame: Baseline through Day 85

  2. Visual Analog Scale (VAS) Pain Score for Subcutaneous Injection Site

    The injection pain VAS score is a participant administered single item scale designed to measure pain using a 0-100 millimeter (mm) horizontal VAS. The severity of pain was categorized by VAS pain score as: no pain (0), mild pain ≤ 30, moderate pain (\>30 and ≤70), and severe pain (\>70). Overall severity of participant's pain is indicated by placing a single mark on the horizontal 100 mm scale from 0 mm (no pain) to 100 mm (worst imaginable pain).

    Time frame: 0 min, 0.25 hours (h), 0.5 h, 1 h, 2 h and 4 h post first injection

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Mirikizumab

    PK: Cmax of Mirikizumab was evaluated.

    Time frame: Pre-dose, [end of infusion (EOI) IV only], Day 1: 6 hours (h), Day 2, Day 4, Day 8, Day 11 (SC only), Day 15, Day 22, Day 29, Day 43, Day 57, Day 71, and Day 85 postdose

  2. PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Mirikizumab

    PK: AUC(0-∞) of Mirikizumab was evaluated.

    Time frame: Pre-dose, [end of infusion (EOI) IV only], Day 1: 6 hours (h), Day 2, Day 4, Day 8, Day 11 (SC only), Day 15, Day 22, Day 29, Day 43, Day 57, Day 71, and Day 85 postdose

  3. PK: AUC From Time Zero to Time T, Where T is the Last Sample With a Measurable Concentration (AUC[0-tlast]) of Mirikizumab

    PK: AUC(0-tlast) of Mirikizumab was evaluated.

    Time frame: Pre-dose, [end of infusion (EOI) IV only], Day 1: 6 hours (h), Day 2, Day 4, Day 8, Day 11 (SC only), Day 15, Day 22, Day 29, Day 43, Day 57, Day 71, and Day 85 postdose

07

Results

Posted Jan 26, 2024

Participant flow

Participant flow — Overall Study
MilestonePlacebo Intravenous (IV)300 Milligram (mg) Mirikizumab IV600 mg Mirikizumab IV1200 mg Mirikizumab IVPlacebo Subcutaneous (SC)200 mg Mirikizumab SC400 mg Mirikizumab SC
Started610101041010
Received at least one dose of study drug610101041010
Completed61010941010
Not completed0001000
Withdrew: Physician decision0001000

Outcome measures

PrimaryNumber of Participants With One or More Drug-Related Treatment-Emergent Adverse Events (TEAEs)

Drug-related TEAEs are any untoward medical occurrence that either occurs or worsens at any time after treatment baseline, and in the opinion of the investigators is possibly related to study drug. A summary of serious adverse events (SAEs) and other non-serious adverse events (NSAEs), regardless of whether or not they were possibly related to study drug, is located in the Reported Adverse Event section.

Time frame:
Baseline through Day 85
Reported as:
Number · participants
Number of Participants With One or More Drug-Related Treatment-Emergent Adverse Events (TEAEs)
participantsPlacebo IV300 mg Mirikizumab IV600 mg Mirikizumab IV1200 mg Mirikizumab IVPlacebo SC200 mg Mirikizumab SC400 mg Mirikizumab SC
Number of Participants With One or More Drug-Related Treatment-Emergent Adverse Events (TEAEs)1341100
PrimaryVisual Analog Scale (VAS) Pain Score for Subcutaneous Injection Site

The injection pain VAS score is a participant administered single item scale designed to measure pain using a 0-100 millimeter (mm) horizontal VAS. The severity of pain was categorized by VAS pain score as: no pain (0), mild pain ≤ 30, moderate pain (\>30 and ≤70), and severe pain (\>70). Overall severity of participant's pain is indicated by placing a single mark on the horizontal 100 mm scale from 0 mm (no pain) to 100 mm (worst imaginable pain).

Time frame:
0 min, 0.25 hours (h), 0.5 h, 1 h, 2 h and 4 h post first injection
Reported as:
Mean · millimeter (mm)
Visual Analog Scale (VAS) Pain Score for Subcutaneous Injection Site
millimeter (mm)Placebo SC200 mg Mirikizumab SC400 mg Mirikizumab SC
0 min36.5 ± 36.330.8 ± 29.542.4 ± 26.0
0.25 h3.5 ± 3.32.9 ± 3.710.6 ± 20.2
0.5 h2.3 ± 2.61.9 ± 3.49.5 ± 23.1
1 h1.0 ± 0.81.6 ± 1.92.0 ± 1.8
2 h1.8 ± 1.01.2 ± 1.52.0 ± 2.0
4 h1.0 ± 0.81.0 ± 1.22.1 ± 2.6
SecondaryPharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Mirikizumab

PK: Cmax of Mirikizumab was evaluated.

Time frame:
Pre-dose, [end of infusion (EOI) IV only], Day 1: 6 hours (h), Day 2, Day 4, Day 8, Day 11 (SC only), Day 15, Day 22, Day 29, Day 43, Day 57, Day 71, and Day 85 postdose
Reported as:
Geometric mean · microgram per milliliter (μg/mL)
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Mirikizumab
microgram per milliliter (μg/mL)300 mg Mirikizumab IV600 mg Mirikizumab IV1200 mg Mirikizumab IV200 mg Mirikizumab SC400 mg Mirikizumab SC
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Mirikizumab145 ± 7266 ± 16511 ± 1014.9 ± 2823.1 ± 44
SecondaryPK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Mirikizumab

PK: AUC(0-∞) of Mirikizumab was evaluated.

Time frame:
Pre-dose, [end of infusion (EOI) IV only], Day 1: 6 hours (h), Day 2, Day 4, Day 8, Day 11 (SC only), Day 15, Day 22, Day 29, Day 43, Day 57, Day 71, and Day 85 postdose
Reported as:
Geometric mean · microgram*day per milliliter (μg*day/mL)
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Mirikizumab
microgram*day per milliliter (μg*day/mL)300 mg Mirikizumab IV600 mg Mirikizumab IV1200 mg Mirikizumab IV200 mg Mirikizumab SC400 mg Mirikizumab SC
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Mirikizumab936 ± 122030 ± 123320 ± 23263 ± 29421 ± 46
SecondaryPK: AUC From Time Zero to Time T, Where T is the Last Sample With a Measurable Concentration (AUC[0-tlast]) of Mirikizumab

PK: AUC(0-tlast) of Mirikizumab was evaluated.

Time frame:
Pre-dose, [end of infusion (EOI) IV only], Day 1: 6 hours (h), Day 2, Day 4, Day 8, Day 11 (SC only), Day 15, Day 22, Day 29, Day 43, Day 57, Day 71, and Day 85 postdose
Reported as:
Geometric mean · μg*day/mL
PK: AUC From Time Zero to Time T, Where T is the Last Sample With a Measurable Concentration (AUC[0-tlast]) of Mirikizumab
μg*day/mL300 mg Mirikizumab IV600 mg Mirikizumab IV1200 mg Mirikizumab IV200 mg Mirikizumab SC400 mg Mirikizumab SC
PK: AUC From Time Zero to Time T, Where T is the Last Sample With a Measurable Concentration (AUC[0-tlast]) of Mirikizumab964 ± 152010 ± 123300 ± 24248 ± 34417 ± 46

Adverse events

Collected over Up To 85 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo IV0/6 (0%)0/6 (0%)5/6 (83.3%)
300 mg Mirikizumab IV0/10 (0%)0/10 (0%)7/10 (70%)
600 mg Mirikizumab IV0/10 (0%)0/10 (0%)9/10 (90%)
1200 mg Mirikizumab IV0/10 (0%)0/10 (0%)3/10 (30%)
Placebo SC0/4 (0%)0/4 (0%)3/4 (75%)
200 mg Mirikizumab SC0/10 (0%)0/10 (0%)4/10 (40%)
400 mg Mirikizumab SC0/10 (0%)0/10 (0%)5/10 (50%)
Most frequent other events
Showing 10 of 36
Most frequent other events
EventPlacebo IV300 mg Mirikizumab IV600 mg Mirikizumab IV1200 mg Mirikizumab IVPlacebo SC200 mg Mirikizumab SC400 mg Mirikizumab SC
ErythemaSkin and subcutaneous tissue disorders1/63/100/100/100/40/100/10
Abdominal painGastrointestinal disorders1/60/100/100/101/40/100/10
BronchitisInfections and infestations0/60/100/100/101/40/100/10
Animal scratchInjury, poisoning and procedural complications0/60/100/100/101/40/100/10
Ligament sprainInjury, poisoning and procedural complications0/60/100/100/101/40/100/10
Aspartate aminotransferase increasedInvestigations1/60/100/100/101/40/100/10
Blood uric acid increasedInvestigations1/61/102/101/101/40/102/10
Platelet count decreasedInvestigations0/60/100/100/101/40/100/10
Upper respiratory tract infectionInfections and infestations1/62/100/100/100/41/101/10
Blood potassium decreasedInvestigations0/60/100/100/100/40/102/10

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Placebo IV300 mg Mirikizumab IV600 mg Mirikizumab IV1200 mg Mirikizumab IVPlacebo SC200 mg Mirikizumab SC400 mg Mirikizumab SCTotal
Mean26.0 ± 6.232.4 ± 6.431.7 ± 5.336.5 ± 6.125.0 ± 5.033.9 ± 7.231.8 ± 6.232.0 ± 6.8
Sex: Female, Male
Sex: Female, Male(Participants)Placebo IV300 mg Mirikizumab IV600 mg Mirikizumab IV1200 mg Mirikizumab IVPlacebo SC200 mg Mirikizumab SC400 mg Mirikizumab SCTotal
Female244405423
Male466645637
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo IV300 mg Mirikizumab IV600 mg Mirikizumab IV1200 mg Mirikizumab IVPlacebo SC200 mg Mirikizumab SC400 mg Mirikizumab SCTotal
Hispanic or Latino00000000
Not Hispanic or Latino61010104101060
Unknown or Not Reported00000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo IV300 mg Mirikizumab IV600 mg Mirikizumab IV1200 mg Mirikizumab IVPlacebo SC200 mg Mirikizumab SC400 mg Mirikizumab SCTotal
American Indian or Alaska Native00000000
Asian61010104101060
Native Hawaiian or Other Pacific Islander00000000
Black or African American00000000
White00000000
More than one race00000000
Unknown or Not Reported00000000
Region of Enrollment
Region of Enrollment(Participants)Placebo IV300 mg Mirikizumab IV600 mg Mirikizumab IV1200 mg Mirikizumab IVPlacebo SC200 mg Mirikizumab SC400 mg Mirikizumab SCTotal
China61010104101060
08

Study locations

2 sites
  • Shanghai Xuhui Central Hospital
    Xuhui District, Shanghai 20031, China
  • Peking University First Hospital
    Beijing, 100034, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Dec 2020, 12 months.

Results were first posted in Jan 2024, 3 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2019
First posted
Oct 24, 2019
StartActual
Dec 4, 2019
Primary completionActual
Dec 11, 2020
CompletionActual
Dec 11, 2020
Results first posted
Jan 26, 2024
Last update
Jan 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04137380
Responsible party
Sponsor
First posted
Oct 24, 2019
Start date
Dec 4, 2019
Primary completion
Dec 11, 2020
Completion
Dec 11, 2020
Results posted
Jan 26, 2024
Last update
Jan 26, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirikizumab

Start the discussion